Hormone-free NKTs provide relief by targeting parts of the brain and skin that are thought to help regulate body temperature. These medications work

rapidly
and
effectively
to relieve symptoms in a hormone-free way.

 

HOW HORMONE-FREE NKTS WORK

NKTs may target just receptors called NK-3, or both NK-1 and NK-3 receptors (known as ‘dual NK receptor antagonists’).

NK-1 and NK-3 receptors

NK-1 and NK-3 receptors are found on cells in your brain called KNDy* (pronounced ‘candy’) neurons. NK-1 receptors are also found in blood vessels in your skin.

KNDy neurons

KNDy neurons are thought to regulate temperature and sleep, but during menopause, falling oestrogen levels mean they become overactive.

sleep disturbance

When this happens, it makes your body’s temperature control system more sensitive, leading to hot flashes, sweating and sleep disturbances. NKTs work by addressing this overactivity, helping restore balance to your body’s control system.

BENEFITS OF HORMONE-FREE NKTS

Benefits_of_hormone-free_NKTs

NKTs are suitable if you prefer not to, or are unable to, use hormones. They can effectively ease symptoms such as

(with or without sweating), leading to improved comfort and quality of life. Some also help you manage
sleep disturbances
, contributing to improved sleep patterns.

COMMON SIDE EFFECTS AND OTHER CONSIDERATIONS

While NKTs can help with menopausal symptoms, it is important to be aware of the potential side effects and other considerations associated with them. Possible side effects include headaches, fatigue, diarrhoea, stomachache, and mild drowsiness.

NKTs do not address all menopause-associated risks, such as bone loss. In addition, if your healthcare provider knows or suspects you have a liver disease (hepatic disorder), they may want to do regular checks while you are taking some hormone-free treatments to make sure your liver is working properly.

The decision to use hormone-free treatments should be made in consultation with your healthcare provider, who can provide personalised guidance based on your individual health history and risk factors.

 

*KNDy is short for kisspeptin, neurokinin B, and dynorphin. These are the names of the proteins made by the KNDy neuron. A neuron is a type of nerve cell that uses proteins and chemicals to send messages around your body. 


    • 1
      Trower M, Anderson RA, Ballantyne E, Joffe H, Kerr M, Steve Pawsey S. Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. Menopause. 2020 May;27(5):498–505.
    • 2
      Veoza (fezolinetant) 45 mg film-coated tablets. Summary of Product Characteristics. Feb 2025.
    • 3
      Pinkerton JV, Simon JA, Joffe H, Maki PM, Nappi RE, Panay N, Soares CN, Thurston RC, Caetano C, Haberland C, Haseli-Mashhadi N, Krahn U, Mellinger U, Parke S, Seitz C, Zuurman L. Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials. JAMA. 2024 Aug 22;332(8):1343–54.
    • 4
      Shifren JL, Gass ML, NAMS Recommendations for Clinical Care of Midlife Women Working Group. The North American Menopause Society recommendations for clinical care of midlife women. Menopause. 2014 Oct;21(10):1038–62.
    • 5
      Christ JP, Navarro VM, Reed SD. Nonhormonal therapies for menopausal vasomotor symptoms. JAMA. 2023 Sep 15;330(13):1278–9.
    • 6
      Rance NE, Dacks PA, Mittelman-Smith MA, Romanovsky AA, Krajewski-Hall SJ. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B, and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol. 2013 Oct;34(3):211–27.
    • 7
      Sergeeva OA, Mazur K, Kernder A, Haas HL, De Luca R. Tachykinins amplify the action of capsaicin on central histaminergic neurons. Peptides. 2022 Jan;150:170729.
    • 8
      Wong BJ, Minson CT. Neurokinin-1 receptor desensitization attenuates cutaneous active vasodilatation in humans. J Physiol. 2006 Oct 5;577(3):1043–51.
    • 9
      Mittelman-Smith MA, Williams H, Krajewski-Hall SJ, McMullen NT, Rance NE. Role for kisspeptin/neurokinin B/dynorphin (KNDy) neurons in cutaneous vasodilatation and the estrogen modulation of body temperature. Proc Natl Acad Sci USA. 2012 Nov 27;109(48):19846–51.
    • 10
      British National Formulary. Fezolinetant. London: National Institute for Health and Care Excellence (NICE); [cited 2025 Apr 14]. Available at: https://bnf.nice.org.uk/drugs/fezolinetant/.
    • 11
      Hager, M., Goldstein, T., Fitz, V., Ott, J. (2024). Elinzanetant, a new combined neurokinin-1/-3 receptor antagonist for the treatment of postmenopausal vasomotor symptoms. Expert Opinion on Pharmacotherapy, 25(7), 783–789.
    • 12
      National Institute on Ageing. Hot Flashes: What can I do? Available at: https://www.nia.nih.gov/health/menopause/hot-flashes-what-can-i-do.